GLP-1 receptor agonists is a popular drug class, with most medications approved for Type 2 diabetes and a few indicated for chronic weight management. Demand is surging for off-label prescriptions of the powerful weight loss drugs, and intermittent shortages are not only causing frustrations among patients but fluctuating the costs.
Insurance companies are increasingly reducing their coverage for GLP-1s or removing them from formularies, which is causing “volatile” pricing changes, GoodRx said March 6.
In a new report, the drug cost tracking company found Mounjaro and Zepbound were the two GLP-1s with the highest price increases. Mounjaro is approved for Type 2 diabetes, and Zepbound is indicated for chronic weight management.
“The highest jump in what people paid [for this drug class] was from June 2023 to July 2023, when over the course of the month, the average out-of-pocket pay amount increased from $92 to $227,” GoodRx said.
At the same time, the cost for older diabetes medications has remained stable, according to prescription fill data between 2018 and 2023.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
